Revolution Medicines, Inc.(RVMD)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
RVMD Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Revolution Medicines, Inc. (RVMD), a Healthcare sector company. RVMD is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), Revolution Medicines, Inc. reports net income of $-644.4M, free cash flow of $-389.6M. Top institutional holders of RVMD by reported 13-F value include BlackRock, FARALLON CAPITAL MANAGEMENT, FMR, based on the most recent SEC filings. RVMD trades on the Nasdaq exchange and files with the SEC under CIK 1628171. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RVMD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Revolution Medicines, Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$-644.4M
Free Cash Flow
Q2 2026
$-389.6M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
Net Income
-88.5% YoYOperating Income
-71.5% YoYEPS (Diluted)
-66.2% YoYTotal Assets
-8.0% YoYOp. Cash Flow
-61.0% YoYFree Cash Flow
-60.9% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 -100.0% | $11.6M -67.3% | $35.4M +20.4% | $29.4M -31.6% | $43.0M |
| Net Income | $-1.13B -88.5% | $-600.1M -37.5% | $-436.4M -75.5% | $-248.7M -32.9% | $-187.1M -73.0% | $-108.2M |
| Operating Income | $-1.18B -71.5% | $-689.5M -41.5% | $-487.2M -88.6% | $-258.3M -37.4% | $-188.0M -69.8% | $-110.7M |
| EPS (Diluted) | $-5.95 -66.2% | $-3.58 +7.3% | $-3.86 -25.3% | $-3.08 -19.8% | $-2.57 -27.9% | $-2.01 |
| Total Assets | $2.35B -8.0% | $2.56B +24.1% | $2.06B +153.9% | $811.9M +10.0% | $738.0M +30.1% | $567.4M |
| Operating Cash Flow | $-897.7M -61.0% | $-557.4M -59.0% | $-350.6M -56.2% | $-224.4M -52.5% | $-147.2M -47.1% | $-100.1M |
| Free Cash Flow | $-913.7M -60.9% | $-567.7M -58.5% | $-358.3M -52.3% | $-235.2M -53.0% | $-153.7M -49.2% | $-103.0M |
Get alerted when RVMD's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Revolution Medicines, Inc. including:
Top Institutional Holders of RVMD
BlackRock, Inc.
$2.6B13,695,790 shFARALLON CAPITAL MANAGEMENT LLC
$2.5B13,550,796 shFMR LLC
$2.3B12,200,422 shBAKER BROS. ADVISORS LP
$2.1B11,443,357 shDarwin Global Management, Ltd.
$2.0B10,629,822 shJupiter Topco LLC
$2.0B10,736,145 shVANGUARD CAPITAL MANAGEMENT LLC
$1.7B9,088,661 shVANGUARD PORTFOLIO MANAGEMENT LLC
$1.6B8,294,855 shNextech Invest, Ltd.
$1.4B7,601,087 shParadigm Biocapital Advisors LP
$1.2B6,361,323 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $2.6B | 13,695,790 |
| FARALLON CAPITAL MANAGEMENT LLC | $2.5B | 13,550,796 |
| FMR LLC | $2.3B | 12,200,422 |
| BAKER BROS. ADVISORS LP | $2.1B | 11,443,357 |
| Darwin Global Management, Ltd. | $2.0B | 10,629,822 |
| Jupiter Topco LLC | $2.0B | 10,736,145 |
| VANGUARD CAPITAL MANAGEMENT LLC | $1.7B | 9,088,661 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1.6B | 8,294,855 |
| Nextech Invest, Ltd. | $1.4B | 7,601,087 |
| Paradigm Biocapital Advisors LP | $1.2B | 6,361,323 |
More Healthcare Companies
View all Healthcare →Put RVMD on your watchlist
Track score changes the day Revolution Medicines, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is RVMD a good stock to buy?
13F Pro's AI-powered analysis of Revolution Medicines, Inc. (RVMD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for RVMD are available on the RVMD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. RVMD is classified as a large company.
Which hedge funds own RVMD?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling RVMD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Revolution Medicines, Inc.'s investment landscape.